Estás usando un navegador no soportado
Usar Internet Explorer está desaconsejado por problemas de seguridad. Para ver correctamente esta web, por favor use cualquier navegador moderno: Chrome, Firefox, Edge, Safari u otro de su elección.
En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias
FILTRAR POR:
8059 ARTÍCULOS , VIENDO DEL 4396 AL 4410
Old and new acetylcholinesterase inhibitors for Alzheimer's disease
Galimberti D, Scarpini E.
Expert Opin Investig Drugs. 2016 Oct;25(10):1181-7. doi: 10.1080/13543784.2016.1216972. Epub 2016 Aug 5.
[Progress of clinical trials in Alzheimer’s disease drugs]
Peng Y, Li PP, Li L, Zhang Y, Hou WZ, Cui DD, Li J, Wang L, Wang QL, Wang XL.
Yao Xue Xue Bao. 2016 Aug;51(8):1185-95.
Weeks J.
J Altern Complement Med. 2016 Aug;22(8):585-7. doi: 10.1089/acm.2016.29008.jjw.
Older patients are still under-represented in clinical trials of Alzheimer's disease
Banzi R, Camaioni P, Tettamanti M, Bertele' V, Lucca U.
Alzheimers Res Ther. 2016 Aug 12;8:32. doi: 10.1186/s13195-016-0201-2.
Treatment strategies in Alzheimer's disease: a review with focus on selenium supplementation
Aaseth J, Alexander J, Bjørklund G, Hestad K, Dusek P, Roos PM, Alehagen U.
Biometals. 2016 Oct;29(5):827-39. doi: 10.1007/s10534-016-9959-8. Epub 2016 Aug 16.
Editorial (Thematic Issue: Current and Perspective Therapeutic Strategies for Alzheimer's Disease)
Piccionello AP, Cappello F.
Curr Pharm Des. 2016;22(26):3935-6. doi: 10.2174/138161282226160801224800.
Bando N, Nakamura Y.
Geriatr Gerontol Int. 2017 Sep;17(9):1306-1312. doi: 10.1111/ggi.12865. Epub 2016 Aug 21.
Editorial: Combining Forces to Improve Alzheimer's Disease Drug Discovery: The Symptomatic Battle
Deguil J, Auffret A, Schenker E, Aujard F, Lamberty Y, Bartrès-Faz D, Blin O, Micallef J, Richardson JC, Bordet R.
CNS Neurol Disord Drug Targets. 2016;15(7):754-5. doi: 10.2174/187152731507160808200737.
Perspectives for treating Alzheimer's disease: a review on promising pharmacological substances
Cazarim Mde S, Moriguti JC, Ogunjimi AT, Pereira LR.
Sao Paulo Med J. 2016 Jul-Aug;134(4):342-54. doi: 10.1590/1516-3180.2015.01980112.
Neuroprotective properties of mitochondria-targeted antioxidants of the SkQ-type
Isaev NK, Stelmashook EV, Genrikhs EE, Korshunova GA, Sumbatyan NV, Kapkaeva MR, Skulachev VP.
Rev Neurosci. 2016 Dec 1;27(8):849-855. doi: 10.1515/revneuro-2016-0036.
Natural Compounds and Neuroprotection: Mechanisms of Action and Novel Delivery Systems
Bagli E, Goussia A, Moschos MM, Agnantis N, Kitsos G.
In Vivo. 2016 09-10;30(5):535-47.
A proposed preventive role for Gamma-hydroxybutyrate (Xyrem(R)) in Alzheimer's disease
Maitre M, Klein C, Mensah-Nyagan AG.
Alzheimers Res Ther. 2016 Sep 6;8(1):37. doi: 10.1186/s13195-016-0205-y.
Devassy JG, Leng S, Gabbs M, Monirujjaman M, Aukema HM.
Adv Nutr. 2016 Sep 15;7(5):905-16. doi: 10.3945/an.116.012187. Print 2016 Sep.
Recent Findings in Alzheimer Disease and Nutrition Focusing on Epigenetics
Athanasopoulos D, Karagiannis G, Tsolaki M.
Adv Nutr. 2016 Sep 15;7(5):917-27. doi: 10.3945/an.116.012229. Print 2016 Sep.
Drug development in Alzheimer's disease: the path to 2025
Cummings J, Aisen PS, DuBois B, Frölich L, Jack CR Jr, Jones RW, Morris JC, Raskin J, Dowsett SA, Scheltens P.
Alzheimers Res Ther. 2016 Sep 20;8:39. doi: 10.1186/s13195-016-0207-9.
Actualización mensual Regístrese para recibir los avisos de actualización
Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.